Huons Biopharma Secures Kuwait Approval for Hutox Botulinum Toxin, Accelerates Middle East Expansion
核心洞察
Huons Biopharma (搜索) obtained marketing authorization for its botulinum toxin product Hutox from Kuwait's health authorities (搜索), marking its first entry into a Gulf Cooperation Council country.
The company appointed Lee Jung-hee as new CEO to accelerate global expansion, particularly targeting the Chinese market where it received NMPA approval in January.
Hutox is now approved in 16 countries worldwide, with the company planning further expansion into GCC countries and other regions including Latin America and Southeast Asia.
Huons Biopharma (搜索) has secured marketing authorization for its botulinum toxin product "Hutox" (known domestically as Liztox) from Kuwait's health authorities (搜索), marking a significant milestone in the company's Middle East expansion strategy. The authorization represents the first entry of Huons Biopharma into a Gulf Cooperation Council (GCC) country and was achieved through collaboration with local partner Al Reyada (搜索).
Strategic Leadership Change Drives Global Expansion
The company recently appointed Lee Jung-hee as its new CEO to spearhead international growth initiatives. Lee, born in 1976 and holding an MBA from Alto University in Finland, brings 23 years of experience in the pharmaceutical industry, having worked at Ibsen Korea, Hanwha Pharmaceutical, Hugel, Daewoong Pharmaceutical, Zetema, and Chong Kun Dang Bio. His expertise spans marketing, sales, and strategic planning in the skin and beauty medical fields, with particular strength in overseas business development during his tenure at Hugel and Daewoong Pharmaceutical.
"It is an important time to start exporting in earnest based on Chinese product approval," said CEO Lee Jung-hee. "We will strengthen our targeting of the Chinese market in the second half of the year and expand research and development of next-generation products to lay the foundation for sustainable growth."
Kuwait Entry Opens Gateway to Regional Markets
Kuwait represents a strategic entry point for Huons Biopharma (搜索)'s Middle East expansion, as the country is considered a market with high demand for beauty and aesthetics among GCC nations. The growing demand for noninvasive cosmetic procedures among high-income consumers is driving expansion of the botulinum toxin market, particularly around dermatology and cosmetic clinics.
Based on this Kuwait authorization, Huons Biopharma (搜索) plans to expand into other GCC countries including the United Arab Emirates (UAE), Saudi Arabia, Qatar, Oman, and Bahrain. The company emphasized its commitment to strengthening global market competitiveness through authorization strategies and quality control systems tailored to each country's specific regulations.
Global Market Presence Expands
Huons Biopharma (搜索) has now obtained marketing authorization for Hutox in 16 countries worldwide. A major breakthrough came in January when the company received approval from China's National Medical Products Administration (搜索) (NMPA) for its 100-unit botulinum toxin product "Hewtox (搜索)," with shipments beginning last month. Currently, the company sells products in 16 countries, including Thailand and Russia.
"Through this Kuwait marketing authorization, we reconfirmed our capabilities in responding to global regulations and our product competitiveness," stated CEO Lee Jeong-hee. "We plan to pursue additional authorizations and expand supply in the GCC and Middle East regions."
Future Expansion Plans
The company is actively proceeding with authorization procedures across multiple regions, including Latin America, Southeast Asia, and the Middle East. Huons Biopharma (搜索) plans to expand global sales in the South American, Middle East, and Southeast Asian markets, building on its established presence in existing markets.